ENSC

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Wall Street analysts forecast ENSC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENSC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ensysce Biosciences Inc revenue for the last quarter amounts to 493.10K USD, decreased -85.58 % YoY.

Ensysce Biosciences Inc. EPS for the last quarter amounts to -1.29 USD, decreased -229.00 % YoY.

Ensysce Biosciences Inc (ENSC) has 7 emplpoyees as of December 15 2025.

Today ENSC has the market capitalization of 5.18M USD.